69409-02-5

Usage

Chemical Properties

Pale Yellow Solid

InChI:InChI=1/C18H19N3O3/c1-11(22)19-13-9-12-5-4-6-14-16(12)15(10-13)18(24)21(17(14)23)8-7-20(2)3/h4-6,9-10H,7-8H2,1-3H3,(H,19,22)

Upstream product

• 61690-44-6 3-acetylaminonaphthalene-1,8-dicarboxylic anhydride 
• 108-00-9 N,N-dimethylethylenediamine 
• 69408-81-7 amonafide 
• 72-89-9 acetylcoenzyme A 
• 23204-38-8 3-amino-naphthalene-1,8-dicarboxylic acid-anhydride 
• 3027-38-1 3-nitro-1,8-naphthalic anhydride 
• 54824-17-8 mitonafide 
• 108-24-7 acetic anhydride 

Relevant academic research and scientific papers

Cancer cell-targeted two-photon fluorescence probe for the real-time ratiometric imaging of DNA damage

Real-time imaging of DNA damage in cancer cells could provide valuable information on the formation and development of cancer. Herein, a two-photon fluorescence probe was discovered. Through sequential ICT processes, it allows successful in vivo visualization of DNA damage in cancer cells by one/two-photon microscopic imaging or by the unaided eye and a hand-held ultraviolet lamp.

Selective and sensitive detection and quantification of arylamine N-acetyltransferase 2 by a ratiometric fluorescence probe

A novel NAT2 specific probe has been developed for sensitive detection of the activity of NAT2. Upon NAT2 catalyzed acetylation of the molecule to N-acetyl-amonafide, the ratiometric response of fluorescence with significant changes in wavelength and intensity is observed. Its significant application potential has been successfully demonstrated in cellular systems.

2,2,2-Trichloro-N-({2-[2-(dimethylamino)ethyl]-1,3-dioxo-2, 3-dihydro-1H-benzo[de]isoquinolin-5-yl}carbamoyl)acetamide (UNBS3157), a novel nonhematotoxic naphthalimide derivative with potent antitumor activity

Amonafide (1), a naphthalimide which binds to DNA by intercalation and poisons topoisomerase IIα, has demonstrated activity in phase II breast cancer trials, but has failed thus far to enter clinical phase III because of dose-limiting bone marrow toxicity. Compound 17 (one of 41 new compounds synthesized) is a novel anticancer naphthalimide with a distinct mechanism of action, notably inducing autophagy and senescence in cancer cells. Compound 17 (2,2,2-trichloro-N-({2-[2-(dimethylamino)ethyl]-1,3-dioxo-2,3-dihydro-1H- benzo[de]isoquinolin-5-yl}carbamoyl)acetamide (UNBS3157)) was found to have a 3-4-fold higher maximum tolerated dose compared to amonafide and not to provoke hematotoxicity in mice at doses that display significant antitumor effects. Furthermore, 17 has shown itself to be superior to amonafide in vivo in models of (i) L1210 murine leukemia, (ii) MXT-HI murine mammary adenocarcinoma, and (iii) orthotopic models of human A549 NSCLC and BxPC3 pancreatic cancer. Compound 17, therefore, merits further investigation as a potential anticancer agent.